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Abstract
Background: The worse prognosis in patients without ST-elevation (non-STEMI) as compared to
ST-elevation myocardial infarction (STEMI), may be due to treatment differences. We aimed to
evaluate the differences in characteristics, treatment and outcome in patients with non-STEMI
versus STEMI in an unselected patient population.
Methods: Individual patient data from all patients in our hospital with a discharge diagnosis of MI
between Jan 2001 and Jan 2002 were evaluated. Follow-up data were obtained until December
2004. Patients were categorized according to the presenting electrocardiogram into non-STEMI or
STEMI.
Results: A total of 824 patients were discharged with a diagnosis of MI, 29% with non-STEMI and
71% with STEMI. Patients with non-STEMI were significantly older and had a higher cardiovascular
risk profile. They underwent less frequently coronary angiography and revascularization and
received less often clopidogrel and ACE-inhibitor on discharge. Long-term mortality was
significantly higher in the non-STEMI patients as compared to STEMI patients, 20% vs. 12%, p =
0.006, respectively. However, multivariate analysis showed that age, diabetes, hypertension and no
reperfusion therapy (but not non-STEMI presentation) were independent and significant predictors
of long-term mortality.
Conclusion: In an unselected cohort of patients discharged with MI, there were significant
differences in baseline characteristics, and (invasive) treatment between STEMI and non-STEMI.
Long-term mortality was also different, but this was due to differences in baseline characteristics
and treatment. More aggressive treatment may improve outcome in non-STEMI patients.
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Myocardial infarction (MI) is usually categorized into
non-ST-elevation myocardial infarction (non-STEMI) and
ST-elevation myocardial infarction (STEMI). Patients with
STEMI should be treated immediately with reperfusion
therapy by either percutaneous coronary intervention
(PCI) or thrombolysis, if admitted within 12 h of symp-
tom onset [1-4]. Patients with non-STEMI should be sta-
bilized medically and high-risk patients should be
scheduled for an early (within days) interventional strat-
egy [5,6].
A previous study has shown that in unselected patients,
mortality was significantly higher in the non-STEMI as
compared to STEMI patients [7]. However, in that study
coronary angiography was only performed in 52%, only
70% of the eligible STEMI patients were treated with
reperfusion therapy and no information was available
with regard to the type of reperfusion therapy. The pur-
pose of our study was to evaluate the baseline characteris-
tics, treatment and prognosis in an unselected consecutive




From January 2001 to January 2002, individual patient
data from all patients with the discharge diagnosis of
acute myocardial infarction at the Isala klinieken (Zwolle,
The Netherlands) were recorded. To avoid double inclu-
sion of patients, only the first admission for MI during the
study period was used.
Non-STEMI patients consisted of only patients admitted
to our center, however, STEMI patients included also
those referred and those diagnosed by paramedics in the
ambulance and transported directly to our center.
According to the presenting ECG, patients were catego-
rized as non-STEMI or STEMI. Patients were diagnosed
with non-STEMI if they had ischemic chest pain classified
as Braunwald class 3 and the presence of at least 1 of the
following criteria: (new) ST depression of more than 1
mm in at least 2 ECG leads or a positive biomarker (Car-
diac Troponin T > 0.05 μg/L, or CK-MB elevation more
than upper limit of normal). STEMI was defined as chest
pain of > 30 minutes' duration and ECG changes with ST
segment elevation of > 2 mm in at least 2 precordial and
> 1 mm in the limb leads.
Data collection and follow-up
We collected the following variables from the patient files:
age, gender, history of hypertension, diabetes, hyperlipi-
demia, smoking, previous myocardial infarction and dis-
charge medication. Follow-up information was obtained
from the patient's general physician or by direct telephone
interview with the patient.
Ethics
The investigation conforms with the principles outlined
in the Declaration of Helsinki (Br Med J 1964, ii: 177).
The study was approved by the Committee on Research
Ethics of the Isala Klinieken, Zwolle.
Statistical analysis
Statistical analysis was performed with the Statistical
Package for the Social Sciences (SPSS Inc., Chicago, IL,
USA) version 12.0.1. Continuous data were expressed as
mean ± standard deviation of mean and categorical data
as percentage, unless otherwise denoted. The analysis of
variance and the chi-square test were appropriately used
for continuous and categorical variables respectively. Cox
proportional hazard regression procedure was performed
to estimate the hazard ratio of mortality of the findings.
Significant variables analyzed are reported with their
respective Hazard ratio (HR) and 95% confidence inter-
vals (CI). For all analyses, statistical significance was
assumed when the two tailed probability value was <
0.05.
Results
During the study period, 824 patients were discharged
with a diagnosis of MI and categorized as non-STEMI 29%
(N = 241) and STEMI 71% (N = 583).
Baseline characteristics
Baseline characteristics are summarized in Table 1.
Patients with non-STEMI were significantly older, more
often female, had more often hypertension and a history
of previous myocardial infarction.
Treatment
Cardiac catheterization and percutaneous coronary inter-
vention (PCI) were significantly less often performed in
non-STEMI patients (Table 2). Coronary artery bypass
grafting (CABG) was performed more often in the non-
STEMI patients, 17% vs. 3%, p < 0.001. At discharge, non-
STEMI patients less frequently received clopidogrel, ACE-
inhibitors or a statin than STEMI patients. Nitrates and
calcium channel blockers were prescribed more often in
the non-STEMI patients. Aspirin and beta blockers were
prescribed equally in both groups (Table 3).
Outcome
At 3 year follow up, mortality was 20% in the non-STEMI
and 12% in the STEMI patients, p = 0.006 (Figure 1). Uni-
variate predictors of mortality in the non-STEMI patients
were age, diabetes, previous myocardial infarction and
not performing CAG (Table 4). The excess mortality could
not be attributed to the higher CABG rate in the non-Page 2 of 7
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0.653, in the non-STEMI and STEMI patients who under-
went CABG.
Univariate predictors of mortality in the STEMI patients
were age, diabetes, previous myocardial infarction, hyper-
tension, previous myocardial infarction and no reper-
fusion (Table 4).
Cox proportional hazard Analysis
The following factors were included in the Cox-regression
analysis: age, gender, diabetes, previous MI, hypertension,
smoking, non-STEMI (STEMI reference) and no reper-
fusion therapy. This analysis revealed that age, diabetes,
hypertension and no reperfusion therapy were signifi-
cantly associated with increased risk of mortality (Table
5).
Discussion
This study identifies important differences in patient char-
acteristics and management among patients discharged
with the diagnosis of non-STEMI versus STEMI in a cohort
of unselected patients. The higher mortality of patients
with non-STEMI was due to differences in baseline charac-
teristics and treatment.
The ratio of STEMI/non-STEMI is higher in our study as
compared to other studies [7]. The is due the fact that,
STEMI patients are consisted of those who are admitted
primarily to our hospital, referred patients and those diag-
nosed by paramedics of the ambulance and transported
directly to our centre for primary PCI. While, non-STEMI
patients are consisted only of those admitted primarily to
our hospital.
Our results are in accordance with a previous study [7],
showing that non-STEMI patients have higher risk profiles
and are treated less often with guideline recommended
medication. The lower mortality rate in our study may be
due to differences in treatment, rates of coronary angiog-
raphy and revascularisation therapy were higher in our
study. The prognosis after MI, for both non-STEMI and
STEMI, in our study is worse as compared to two previous
registries: the Euro Heart Survey of Acute Coronary Syn-
dromes (EHS-ACS) and the Global Registry of Acute Cor-
onary Events (GRACE) [8,9]. Possibly, in both GRACE
Table 1: Baseline
STEMI non-STEMI
Variable (N = 583) (N = 241) P-value
Age, Y, Mean ± SD 63 ± 12 67 ± 12 <0.001
Female gender, n (%) 150/582 (26) 77/240 (32) 0.07
Diabetes, n (%) 80/568 (14) 37/234 (16) 0.53
Hypertension, n (%) 199/529 (38) 101/229 (44) 0.09
Hyperlipidemia, n (%) 126/406 (31) 76/207 (37) 0.16
Smoking, n (%) 251/558 (45) 70/232 (30) <0.001
Previous MI, n (%) 81/578 (14) 45/233 (19) 0.06
MI = myocardial infarction
Table 2: Treatment and outcome
STEMI non-STEMI P-value
CAG, n (%) 540/583 (93) 189/241 (78) <0.001
Number of vessel disease
1, n (%) 242/540 (45) 65/189 (34) 0.025
≥2, n (%) 292/540 (54) 116/189 (61)
No-CAD, n (%) 6/540 (1) 8/189(4)
Reperfusion 510/583 (87) 140/241 (58) <0.001
PCI, n (%) 481/583 (83) 99/241 (41) <0.001
Thrombolysis, n (%) 9/583 (2.0) -
CABG, n (%) 20/583 (3) 41/241 (17) <0.001
Conservative, n (%) 73/583 (13) 101/241 (42) <0.001
Death, n (%) 71/574 (12) 47/236 (20) 0.006
CAG = coronary angiography, CAD = coronary artery disease, PCI = percutaneous coronary intervention, CABG = coronary artery bypass 
graftingPage 3 of 7
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excluded. For example, patients dying within 24 h of
admission were excluded from GRACE.
Furthermore, compared to our study, many large scale
randomized trials have reported lower mortality rates at
one year follow up after MI [10-14]. The reason for this
difference in outcome may due to low external validity of
these trials due to numerous inclusion and exclusion cri-
teria in these trials. Therefore, their results cannot be rea-
sonably applied to patients in routine clinical practice
[15]. Nevertheless, large scale clinical trials provide the
most reliable data on the effects of treatment. Results of
registries are suggested to be more externally valid than
randomized trials because they include more high risk
patients and are done in a real world setting [16,17], how-
ever registries have also several limitations.
Reasons for different outcomes
The fact that non-STEMI patients were older, had higher
risk profiles, were more often treated conservatively and
less frequently received guideline recommended medica-
tion on the time of discharge, might possibly explain the
difference in mortality rate. These results are in accord-
ance with a previous study, showing that an early invasive
management strategy is not utilized in many high-risk
patients. An invasive strategy appears to be reserved for
patients without significant co-morbidities and with a
lower risk of in-hospital mortality [18]. However, in
patients older than 75 years of age, a routine early invasive
strategy may significantly improve clinical outcomes [19].
Finally, the fact that circumflex artery occlusions are more
likely to present as non-STEMI than as STEMI might con-
tribute to the worse outcome in non-STEMI patients [20].
Challenges to improve outcome
The outcomes in patients with acute coronary syndromes
have improved over time. This was associated with the use
of antiplatelet and antithrombotic therapies and the
increased utilization of revascularization [21]. However,
despite these improvements non-STEMI patients may
have worse outcome [22]. Other factors than patient char-
acteristics and treatment strategy that may account for
worse outcome in non-STEMI are the fact that identifica-
tion of MI is often delayed due to lack of definitive ECG
abnormalities and timing of cardiac troponin elevation
[23,24]. In addition, almost half of patients with non-
STEMI have other symptoms than chest pain when first
seen, which may contribute to delayed diagnosis [25].
The question remains how we can further improve the
outcome of patients with non-STEMI. This may be
achieved by a multifactorial approach; first, identifying
high risk patients, which can be done through a good clin-
ical evaluation of medical history, physical examination,
electrocardiogram (ECG) and cardiac biomarkers e.g.
myoglobin, cardiac troponin and CK-MB [26,27]. Second,
using the TIMI Risk Score, a simple clinical score that may
be used by the clinician at the bedside for risk assessment
and therapeutic decision-making, may improve patient
management [28,29]. Third, an early invasive strategy
may improve outcome. Several clinical trials have shown
Mortality curves stratified according to MI categoryFigure 1
Mortality curves stratified according to MI category.
Table 3: Discharge medication
Medication STEMI non-STEMI P-value
Aspirin, n (%) 472/552 (86) 187/221 (85) 0.75
Beta blocker, n (%) 484/553 (88) 188/221 (85) 0.36
Clopidogrel, n (%) 381/553 (69) 91/227 (40) <0.001
Statines, n (%) 356/552 (65) 126/221 (57) 0.052
ACE-inhibitor, n (%) 300/553 (54) 87/221 (39) <0.001
Nitrate, n (%) 67/447 (15) 65/221 (29) <0.001
Calcium channel blocker n (%) 16/446 (4) 40/221 (18) <0.001
ACE = angiotensin converting enzymePage 4 of 7
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grater when combined with early initiation of glycopro-
tein IIb/IIIa inhibitors [18,22,30-32]. Finally, recent data
from the CRUSADE (Can Rapid risk stratification of
Unstable angina patients Suppress ADverse outcomes
with Early implementation of the ACC/AHA guidelines)
demonstrated that guideline recommended medication is
underused despite their proven clinical benefit [33]. Treat-
ing patients according to the current guidelines [1,5] will
improve prognosis after MI, as has been reported in recent
studies [34-36].
Future trials
All the above mentioned trials have increased our knowl-
edge with regard to how we should treat high-risk patients
with non-STEMI. However, very early aggressive therapy
in non-STEMI patients, as is performed in STEMI, remains
a field for further research. Further studies are warranted
to evaluate whether immediate cardiac catheterization
and reperfusion in high-risk non-STEMI patients will fur-
ther improve the outcome.
Limitations
Although we tried to register all patients with AMI, it is
however, not possible to include all patients e.g. STEMI
patients that are not referred for atypical chest pain or are
presented too late. However, when comparing only
patients admitted directly to our hospital, results
remained unchanged. Other factors such as co-morbidity
or contraindications for each considered treatment may
account for differences in outcome. Thus selection bias
may play a role in our study. Other factors such as history
of stroke, neoplasm and depression mat affect both treat-
ment and outcome, however, we have no data regarding
these variables. Furthermore, we have no separate date on
bundle branch block MI (BBBMI), as they seem to have
worse outcome [7]. However in the presence of left
BBBMI, the Wellens criteria [37] were used to determine
whether a patient has STEMI or non-STEMI. Finally, this
study reports the treatment and outcome in AMI patients
discharged in 2001 and it may not fully reflect current
care. By that time the available national guidelines already
recommended intensive antithrombotic agents.
Conclusion
This study shows important differences in baseline charac-
teristics, treatment and prognosis between non-STEMI
and STEMI patients. A more invasive therapy and guide-
line recommended treatment might further improve out-
come, especially in the non-STEMI population.
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Table 5: Hazard ratios of mortality of the significant factors in the multivariate model
Variable HR 95% CI P-value
Age, per year 1.06 1.02–1.10 0.002
Female gender 1.01 0.63–1.90 0.75
Diabetes 1.78 1.01–3.17 0.04
Previous MI 1.74 0.98–3.09 0.06
Hypertension 171 1.01–2.88 0.04
Smoking 1.49 0.75–2.94 0.25
MVD 1.68 0.71–4.0 0.24
Non-STEMI* 1.11 0.64–1.93 0.71
No reperfusion 2.95 1.64–5.29 <0.001
MI = myocardial infarction, MVD = multi vessel disease, * STEMI is reference group, Reperfusion (PCI or CABG).
Table 4: Univariate analysis; predictors of mortality
Non-STEMI STEMI
Variable OR 95% CI P-value OR 95% CI P-value
Age per year 1.14 1.09–1.20 <0.001 1.10 1.08–1.14 <0.001
Female gender 0.85 0.43–1.68 0.64 0.58 0.33–1.02 0.06
Diabetes 4.64 2.21–10.15 <0.001 3.6 1.93–6.72 <0.001
Previous MI 4.42 2.12–9.21 <0.001 2.18 1.51–5.24 0.001
Hypertension 1.03 0.53–2.02 0.93 2.41 1.36–4.29 0.003
Smoking 0.58 0.26–1.30 0.19 0.39 0.21–0.74 0.004
No reperfusion 8.34 3.70–18.70 <0.001 4.4 2.60–7.60 <0.001
MI = myocardial infarctionPage 5 of 7
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